IN2015DN00542A - - Google Patents
Info
- Publication number
- IN2015DN00542A IN2015DN00542A IN542DEN2015A IN2015DN00542A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A IN 542DEN2015 A IN542DEN2015 A IN 542DEN2015A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A
- Authority
- IN
- India
- Prior art keywords
- compositions
- disorders
- methods
- treating
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to compositions and methods for treating eye diseases and disorders. More specifically the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676530P | 2012-07-27 | 2012-07-27 | |
| US201361756321P | 2013-01-24 | 2013-01-24 | |
| PCT/US2013/052264 WO2014018856A1 (en) | 2012-07-27 | 2013-07-26 | Compositions and treatment for eye diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00542A true IN2015DN00542A (en) | 2015-06-26 |
Family
ID=49997851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN542DEN2015 IN2015DN00542A (en) | 2012-07-27 | 2013-07-26 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150216877A1 (en) |
| EP (1) | EP2877184B1 (en) |
| JP (1) | JP6209777B2 (en) |
| KR (1) | KR102097663B1 (en) |
| CN (2) | CN104661663A (en) |
| AU (1) | AU2013295645B2 (en) |
| BR (1) | BR112015001847A8 (en) |
| CA (1) | CA2880027C (en) |
| DK (1) | DK2877184T3 (en) |
| ES (1) | ES2759781T3 (en) |
| HK (1) | HK1210968A1 (en) |
| HU (1) | HUE046963T2 (en) |
| IL (1) | IL236920B (en) |
| IN (1) | IN2015DN00542A (en) |
| MX (1) | MX362185B (en) |
| NZ (1) | NZ704247A (en) |
| PL (1) | PL2877184T3 (en) |
| PT (1) | PT2877184T (en) |
| WO (1) | WO2014018856A1 (en) |
| ZA (1) | ZA201500561B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| HUE055562T2 (en) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| MX2015013186A (en) | 2013-03-15 | 2016-04-15 | Glia Llc | Cranial delivery of pharmaceuticals. |
| WO2015080758A1 (en) * | 2013-11-27 | 2015-06-04 | Al-Qahtani Ahmed H | Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca |
| RU2016143081A (en) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES |
| CA2956919C (en) | 2014-07-21 | 2022-07-19 | Glia, Llc | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids |
| WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (en) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR101960023B1 (en) * | 2016-12-21 | 2019-03-20 | 김보경 | Carbon dioxide generator |
| WO2021163253A1 (en) * | 2020-02-12 | 2021-08-19 | Glia, Llc | Progesterone combinations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102656A (en) | 1983-07-29 | 1992-04-07 | The Mennen Company | Antiperspirant creams |
| US4937069A (en) | 1985-11-15 | 1990-06-26 | Bristol-Myers Squibb Company | Anhydrous semi-solid antiperspirant suspension |
| US5069897A (en) | 1987-10-16 | 1991-12-03 | The Proctor & Gamble Company | Antiperspirant creams |
| US6659985B2 (en) | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| US7572780B2 (en) | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| WO2009046967A1 (en) * | 2007-10-08 | 2009-04-16 | Fovea Pharmaceuticals Sa | Aqueous ophthalmic formulations |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| CN101757622A (en) * | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | Drug composition for ocular inflammation resistance |
| BR112012007473A2 (en) * | 2009-10-02 | 2019-05-07 | Foamix Ltd | tetracycline topical compositions and methods of use |
-
2013
- 2013-07-26 PL PL13823485T patent/PL2877184T3/en unknown
- 2013-07-26 CN CN201380039713.2A patent/CN104661663A/en active Pending
- 2013-07-26 JP JP2015524465A patent/JP6209777B2/en active Active
- 2013-07-26 CA CA2880027A patent/CA2880027C/en active Active
- 2013-07-26 WO PCT/US2013/052264 patent/WO2014018856A1/en active Application Filing
- 2013-07-26 IN IN542DEN2015 patent/IN2015DN00542A/en unknown
- 2013-07-26 ES ES13823485T patent/ES2759781T3/en active Active
- 2013-07-26 BR BR112015001847A patent/BR112015001847A8/en not_active Application Discontinuation
- 2013-07-26 AU AU2013295645A patent/AU2013295645B2/en active Active
- 2013-07-26 CN CN201710063950.2A patent/CN107595857A/en active Pending
- 2013-07-26 EP EP13823485.1A patent/EP2877184B1/en active Active
- 2013-07-26 HU HUE13823485A patent/HUE046963T2/en unknown
- 2013-07-26 MX MX2015001250A patent/MX362185B/en active IP Right Grant
- 2013-07-26 US US14/417,640 patent/US20150216877A1/en not_active Abandoned
- 2013-07-26 DK DK13823485T patent/DK2877184T3/en active
- 2013-07-26 NZ NZ704247A patent/NZ704247A/en unknown
- 2013-07-26 KR KR1020157004782A patent/KR102097663B1/en active IP Right Grant
- 2013-07-26 PT PT138234851T patent/PT2877184T/en unknown
-
2015
- 2015-01-25 IL IL236920A patent/IL236920B/en active IP Right Grant
- 2015-01-26 ZA ZA2015/00561A patent/ZA201500561B/en unknown
- 2015-12-03 HK HK15111942.9A patent/HK1210968A1/en unknown
-
2016
- 2016-12-15 US US15/380,741 patent/US9925201B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX362185B (en) | 2019-01-08 |
| PL2877184T3 (en) | 2020-04-30 |
| JP2015524434A (en) | 2015-08-24 |
| US9925201B2 (en) | 2018-03-27 |
| KR102097663B1 (en) | 2020-04-06 |
| ZA201500561B (en) | 2016-04-28 |
| CA2880027C (en) | 2021-12-07 |
| AU2013295645A1 (en) | 2015-02-05 |
| KR20150038311A (en) | 2015-04-08 |
| CN104661663A (en) | 2015-05-27 |
| CN107595857A (en) | 2018-01-19 |
| US20150216877A1 (en) | 2015-08-06 |
| AU2013295645B2 (en) | 2017-08-24 |
| BR112015001847A2 (en) | 2017-07-04 |
| EP2877184B1 (en) | 2019-09-04 |
| ES2759781T3 (en) | 2020-05-12 |
| PT2877184T (en) | 2019-12-02 |
| EP2877184A1 (en) | 2015-06-03 |
| DK2877184T3 (en) | 2019-12-09 |
| NZ704247A (en) | 2018-04-27 |
| HK1210968A1 (en) | 2016-05-13 |
| EP2877184A4 (en) | 2016-03-30 |
| WO2014018856A1 (en) | 2014-01-30 |
| BR112015001847A8 (en) | 2021-09-08 |
| JP6209777B2 (en) | 2017-10-11 |
| MX2015001250A (en) | 2015-10-22 |
| IL236920B (en) | 2018-06-28 |
| CA2880027A1 (en) | 2014-01-30 |
| US20170189413A1 (en) | 2017-07-06 |
| HUE046963T2 (en) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00542A (en) | ||
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| MX2017013562A (en) | Microbiome regulators and related uses thereof. | |
| EP3185876A4 (en) | Compositions and methods for treatment of neurological disorders | |
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| EP3024497A4 (en) | Methods and compositions for treating brain diseases | |
| EP3182977A4 (en) | Compositions and methods to treat vision disorders | |
| EP3160493A4 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| EP3086809A4 (en) | Compositions and methods of treating ocular diseases | |
| MX2015003701A (en) | Treatment compositions. | |
| EP3515444A4 (en) | Composition for treating ocular diseases and methods of usage and making | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EP3481958A4 (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| EP3370709A4 (en) | Use of proteasome inhibitors to treat ocular disorders | |
| EP3082427A4 (en) | Compositions and methods for treatment of glaucoma | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP3402511A4 (en) | Compositions and methods for treatment of ocular diseases | |
| EP2569018A4 (en) | Humanized ttc and methods of use thereof | |
| EP3003341A4 (en) | Compositions and methods for treatment of retinal degenerative diseases | |
| EP2999464A4 (en) | Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms | |
| AU2016349439A8 (en) | Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders |